NVCR
NovoCure Limited
stockNASDAQ
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 15.83 | 2026-09-28 | -5.62% | -6.808 |
| 1M | 17.94 | 2026-09-04 | -16.72% | 0.576 |
| 3M | 17.32 | 2026-07-06 | -13.74% | -0.031 |
| 6M | 10.55 | 2026-04-06 | +41.61% | 1.014 |
| 1Y | 14.50 | 2025-10-06 | +3.03% | 1.516 |
| 2Y | 14.72 | 2024-10-04 | +1.50% | — |
| 5Y | 110.17 | 2021-10-05 | -86.44% | 1.406 |
NovoCure Limited (NASDAQ:NVCR) stock price today is $14.94, and today's volume is 1,695,114. NVCR is down 6.156% today. The 30 day average volume is 1.11M. NVCR market cap is $1.74B with 116.45M shares outstanding.